SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458508093617v1
14/8/1068    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Furby, J
Right arrow Articles by Kapoor, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Furby, J
Right arrow Articles by Kapoor, R
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

research-article

Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis

J Furby

Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom j.furby{at}ion.ucl.ac.uk

T Hayton

Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom

V Anderson

Dementia Research Centre, Institute of Neurology, London, United Kingdom

D Altmann

London School of Hygiene and Tropical Medicine, London, United Kingdom

R Brenner

Department of Neurology, Royal Free Hospital, London, United Kingdom

J Chataway

National Hospital for Neurology and Neurosurgery, London, United Kingdom

RAC Hughes

Department of Clinical Neuroscience, King's College London, London, United Kingdom

KJ Smith

Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom

DH Miller

Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom

R Kapoor

Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom

Background

Neuroaxonal loss is a pathological substrate of disability in progressive multiple sclerosis (MS) and can be estimated in vivo by measuring tissue atrophy on magnetic resonance imaging (MRI). While there is some evidence that brain atrophy correlates better with disability than T2 lesion load in secondary progressive MS, the clinical relevance of atrophy within specific regions of the central nervous system requires further evaluation.

Methods

Clinical and MRI examinations were performed in 117 subjects with secondary progressive MS. MRI analysis included measures of normalized brain volume (NBV), normalized grey matter (NGMV) and white matter volume (NWMV), central cerebral volume (CCV), spinal cord cross-sectional area (SCCA), and brain T2 and T1 lesion volume. Clinical assessments included the expanded disability status scale (EDSS) and MS functional composite (MSFC).

Results

All MRI measures correlated significantly with the MSFC score, with the strongest correlation being for the NBV (r = 0.47; P < 0.001). NBV and SCCA were the only significant independent predictors of the MSFC score in a stepwise regression model containing all the MRI measures, and SCCA was the only MRI measure to show a significant association with the EDSS. While NGMV had stronger correlations with the clinical variables than NWMV, NBV was more correlated with clinical impairment than either measure.

Conclusions

This data suggests that measures of atrophy, particularly of the whole brain and spinal cord, are relevant and useful disease markers in secondary progressive MS.

Key Words: atrophy • disability • MRI • multiple sclerosis • secondary progressive multiple sclerosis

This version was published on September 1, 2008

Multiple Sclerosis, Vol. 14, No. 8, 1068-1075 (2008)
DOI: 10.1177/1352458508093617


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Arch NeurolHome page
M. H. Sombekke, C. Lukas, J. B. A. Crusius, D. Tejedor, J. Killestein, D. Arteta, A. Martinez, B. M. J. Uitdehaag, D. L. Knol, A. S. Pena, et al.
HLA-DRB1*1501 and Spinal Cord Magnetic Resonance Imaging Lesions in Multiple Sclerosis
Arch Neurol, December 1, 2009; 66(12): 1531 - 1536.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
J Furby, T Hayton, D Altmann, R Brenner, J Chataway, K. Smith, D. Miller, and R Kapoor
Different white matter lesion characteristics correlate with distinct grey matter abnormalities on magnetic resonance imaging in secondary progressive multiple sclerosis
Multiple Sclerosis, June 1, 2009; 15(6): 687 - 694.
[Abstract] [PDF]



Advertisement